Collegium Pharmaceutical Releases 2026 Financial Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Collegium Pharmaceutical announced its 2026 full-year financial guidance and provided a business update. Financial Guidance for 2026: Product revenues, net are expected in the range of $805 million to $825 million. Jornay PM net revenue is expected in the range of $190 million to $200 million. Adjusted EBITDA is expected in the range of $455 million to $475 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COLL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COLL
Wall Street analysts forecast COLL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COLL is 56.75 USD with a low forecast of 55.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 44.820
Low
55.00
Averages
56.75
High
60.00
Current: 44.820
Low
55.00
Averages
56.75
High
60.00
About COLL
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Collegium Pharmaceutical EVP Scott Dreyer Sells 17,600 Shares for ~$847,800
- Executive Transaction Overview: On December 8, 2025, Collegium Pharmaceutical's EVP Scott Dreyer exercised options and immediately sold 17,600 common shares for approximately $847,800, indicating a strategic liquidity management approach by the executive.
- Holding Change Analysis: Following the transaction, Dreyer's direct holdings remained at 103,613 shares, reflecting no net gain in ownership and demonstrating confidence in the company's long-term prospects.
- Trading Plan Context: The transaction was executed under a Rule 10b5-1 trading plan adopted on September 3, 2025, indicating that Dreyer's sale was prearranged rather than discretionary, which mitigates market speculation regarding his motivations.
- Company Financial Outlook: Collegium Pharmaceutical showed strong performance in 2025 and is expected to benefit from the success of its ADHD and pain medication portfolio in 2026, with adjusted EBITDA expectations raised from $455 million to $475 million, highlighting the company's growth potential.
Continue Reading
Collegium Pharmaceutical EVP Dreyer Sells 17,600 Shares for ~$847,800
- Insider Sale: Collegium Pharmaceutical's EVP Scott Dreyer sold 17,600 shares through options exercise for approximately $847,800, reducing his direct holdings to 103,613 shares, indicating a liquidity need despite the company's strong performance.
- Stock Surge: COLL shares surged nearly 60% in 2025, reaching an all-time high of $50.79 on December 29, reflecting strong market confidence in the company's ADHD and pain medication portfolio, which is expected to drive future growth.
- Upgraded Financial Outlook: Collegium raised its Q4 2025 adjusted EBITDA guidance from $455 million to $475 million, with Q1-Q3 EBITDA already at $401.18 million, showcasing the company's sustained financial strength.
- Compliance with Trading Plan: Dreyer's share sale was executed under a 10b5-1 trading plan, indicating compliance with regulations and alleviating concerns over insider trading, while also laying a foundation for the company's future growth.
Continue Reading